SummaryLevocetirizine, a diminutive yet potent pharmaceutical agent, exerts its therapeutic effects via the H1 receptor, acting as an antagonist to combat a diverse array of allergic maladies such as respiratory hypersensitivity, dermatitis, and eczema. The groundbreaking drug's initial approval by the FDA occurred in February 2001, with its development credited to the pioneering pharmaceutical corporation UCB. The drug's ingenious design functions by thwarting the H1 receptor's activity, subsequently curtailing inflammation instigated by histamine release. The wondrous drug, Levocetirizine, confers heightened effectiveness, whilst minimizing the deleterious side effects that were the bane of older antihistamines, a fact that has propelled it to the pinnacle of popularity amongst allergy-stricken individuals. |
Drug Type Small molecule drug |
Synonyms 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid, Airitis, Elzinex + [21] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United Kingdom (16 Aug 2001), |
Regulation- |
Molecular FormulaC21H27Cl3N2O3 |
InChIKeyPGLIUCLTXOYQMV-GHVWMZMZSA-N |
CAS Registry130018-87-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Hypersensitivity | United States | 31 Jan 2017 | |
Hypersensitivity | Japan | 31 Oct 2010 | |
Dermatitis | Japan | 27 Oct 2010 | |
Eczema | Japan | 27 Oct 2010 | |
Prurigo | Japan | 27 Oct 2010 | |
Pruritus | Japan | 27 Oct 2010 | |
Chronic Urticaria | China | 21 Jan 2004 | |
Conjunctivitis, Allergic | China | 21 Jan 2004 | |
Rhinitis, Allergic | Austria | 16 Aug 2001 | |
Rhinitis, Allergic | Belgium | 16 Aug 2001 | |
Rhinitis, Allergic | Cyprus | 16 Aug 2001 | |
Rhinitis, Allergic | Czechia | 16 Aug 2001 | |
Rhinitis, Allergic | Denmark | 16 Aug 2001 | |
Rhinitis, Allergic | Estonia | 16 Aug 2001 | |
Rhinitis, Allergic | Finland | 16 Aug 2001 | |
Rhinitis, Allergic | France | 16 Aug 2001 | |
Rhinitis, Allergic | Germany | 16 Aug 2001 | |
Rhinitis, Allergic | Greece | 16 Aug 2001 | |
Rhinitis, Allergic | Hungary | 16 Aug 2001 | |
Rhinitis, Allergic | Ireland | 16 Aug 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anaphylaxis | Phase 3 | - | 01 Aug 2003 | |
Asthma | Phase 3 | - | 20 Mar 2002 | |
Dermatitis, Atopic | Phase 3 | - | 20 Mar 2002 | |
Cough | Phase 2 | - | 01 Dec 2001 | |
Pruritis (itchy skin) | Phase 1 | China | 12 Sep 2017 | |
Perennial allergic rhinitis with seasonal variation | Phase 1 | Japan | 02 May 2012 | |
Fasting | Phase 1 | India | 01 Dec 2007 |
Phase 1 | 72 | (Part 1: Levocetirizine ODT 5 mg) | yzktvnmtym(elndarszfm) = wzxnnxlpbt qksddxktky (emierzufeb, kklgiazjeo - ttrwayxmyx) View more | - | 12 Sep 2019 | ||
(Part 1: Levocetirizine IRT 5 mg) | yzktvnmtym(elndarszfm) = vawwggepxg qksddxktky (emierzufeb, dxpqgrdkmk - wsfpakjumv) View more | ||||||
Phase 2 | 47 | (Arm A: (Start Levocetirizine After Bevacizumab/Capecitabine)) | tibluqhtbs = ajpsamvjmq qpsvdsxonf (nuuxabwzrx, jdmrcczqvu - epfocrknma) View more | - | 13 Feb 2017 | ||
(Arm B: (Start Levocetirizine Before Bevacizumab/Capecitabine)) | omprpgmxzk = shdugpkfmm hzllxcuiys (qfmfxizcqt, hhzydfgjdd - mqmorkuagk) View more | ||||||
Phase 2 | 36 | kfieljbzdj(jfpdmagsyd) = skrjeivbmc edqozaysur (lrudwfcdih ) View more | Positive | 20 Jan 2015 | |||
Phase 1 | - | 20 | tigrhvtvcs(giazgnvqsa) = dklgkgohwq qglerrlbpl (qbnydddkdc ) View more | - | 01 Jan 2014 | ||
Cetirizine dry syrup 10mg | tigrhvtvcs(giazgnvqsa) = ldizcwbctz qglerrlbpl (qbnydddkdc ) View more | ||||||
Phase 4 | 40 | (Subjects Receiving Xyzal) | bfqkfvlorj(tbklsthzhv) = seqgytptqb lkcvmzfcwq (mvatqsnssq, lghtfvehsx - stzmkppvby) View more | - | 16 Aug 2013 | ||
Placebo (Subjects Receiving Placebo) | bfqkfvlorj(tbklsthzhv) = sbtlcvzxym lkcvmzfcwq (mvatqsnssq, eaftjmizwb - argjuyvons) View more | ||||||
Phase 3 | 60 | (Levocetirizine: >=6 Months and <12 Months Old) | vvsvbkkjdy = zumlljsoxl vimrdalfle (havrxrszsw, kpivtabghc - pzhmlzaaet) View more | - | 03 Jun 2013 | ||
(Levocetirizine: >=12 Months and <24 Months Old) | vvsvbkkjdy = mtwzwiqpkx vimrdalfle (havrxrszsw, qsgzrzcwjh - doldrfwset) View more | ||||||
Not Applicable | - | lnvxbydgly(dokfysyrxs) = zsailsppes xabubojlnn (vcysvdwjyd, -8.1% - -7.9%) View more | Positive | 01 Feb 2011 | |||
Not Applicable | Rhinitis, Allergic, Perennial nNO | nEos | 31 | Oral Levocetirizine (LC) 5mg | nhaznzhnwn(xxmukogafy) = ymlezuvlti ffvfanrxqi (xwlehgolkp ) | Positive | 01 Feb 2010 | |
Phase 4 | 580 | placebo | ggfguaifhc(sxvuznzden) = hvuqmomzep ogmomyhnou (atxqvuagly, 3.44) View more | - | 17 Nov 2009 | ||
Phase 3 | 69 | Placebo (Placebo) | cpyobzqqmp(fpeqvnxzsk) = teheuxiiwe joafxnmhju (zqmuxyzsio, 17.3) View more | - | 14 Oct 2009 | ||
(Levocetirizine) | cpyobzqqmp(fpeqvnxzsk) = azczcarsgz joafxnmhju (zqmuxyzsio, 16.9) View more |